Neurology / Research

Exploring neurological pathways, in the blink of an eye

Subscribe for a free copy of the latest 2019 publication from

Dr Murray Johns
The Assessment of ‘Sleepiness’ in Human Drug Trials: A New Perspective

Exploring new pathways

Optalert’s BlinQTM system is transforming the way medical researchers measure and assess drowsiness or wakefulness, and has potential to identify biomarkers for monitoring neurological disorders.
Studies are currently being undertaken in the field of neurological disorders to find potential biomarkers for illnesses, such as:

  • Epilepsy
  • Alzheimer’s
  • Parkinson’s
  • Depression
  • Traumatic brain injury (TBI)
  • Other neurological disorders

Did you know there are various organisations that offer grants, to find precursors and biomarkers of neurological conditions? Find out how Optalert technology could help you explore new research pathways. Contact:

In 2018, Optalert introduced the term blepharometry to describe their unique form of objective measurement of eyelid movement. This innovative technology gives researchers the power to identify, track and ultimately could help to detect biomarkers and other precursors of neurological disorders to allow for early intervention.

The use of blepharometry could have the potential to:

  • find neurological biomarkers
  • screen patients to allow for early intervention
  • identify stages of disease progression
  • monitor response to treatment, and
  • improve the accuracy and efficiency of clinical trials

If you are working in a neurological or other research field and would like to know how Optalert could assist with your research, don’t hesitate to contact us today at